Establishment of a national registry for the evaluation and improvement of risk-adjusted prevention for hereditary breast and ovarian cancer

Recruiting

• Conditions: C50; C56; Malignant neoplasm of breast; Malignant neoplasm of ovary

• Registration Number: DRKS00017837
• Lead Sponsor: Zentrum Familiärer Brust- und Eierstockkrebs Uniklinikum Köln

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 25000

Inclusion Criteria

fulfilled clinical inclusion criteria for a hereditary burden of breast and/or ovarian cancer
- Pathogenic germline variant detected in the familiy
- Relevance to therapy (e.g. PARPi)
- Needed from another medical point of view

Exclusion Criteria

None of the above criteria fulfilled

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation and improvement of risk-adjusted prevention for hereditary breast and ovarian cancer on the basis of gene panel tests in an evidence-/ knowledge-generating care concept by<br>1. the identification of tumour subtypes and subtype specific outcomes of pre-ventive and therapeutic measures, esp. age-specific tumour risks, histological subtype, disease free / progression free / overall survival, quality of life and quality of care, and<br>2. the development and implementation of a continuous education program based on outcome measures in order to improve risk and genetic literacy of counsellors and counselees.